Find and Pitch Jounalists, Get Your Story Covered

Tags: biotechnology CRISPR drug development FDA Pharmaceuticals

	Profile	Recent Articles on Subject
1	Meghana Keshavan STAT News Biotech nerd and writer @statnews. biotechwriting	The view from overseas on tumult in U.S. science - 18 days ago The biotech news stories you need to read today - 19 days ago The biotech news stories we’re keeping an eye on - about 2 months ago Eli Lilly seeks to join lawsuit on compounded drugs - about 2 months ago The biotech news roundup to start your week - 4 months ago The biotech news you need to read today - 4 months ago Element Biosciences raises another massive round - 8 months ago The biotech news you missed this week - 8 months ago STAT+: More tumult at BIO amid the company’s fourth CEO in four years - 9 months ago How resurrecting extinct species might impact medicine - 11 months ago Lawmakers want to add more Chinese biotechs to defense list - 11 months ago The Senate health committee looks into its first subpoena in 40 years - about 1 year ago The biotech updates you need to read today - about 1 year ago The legal pathway for experimental, ultra-rare disease treatments is rocky and expensive - about 1 year ago FDA chastens pet companies over antibiotics - about 1 year ago The biotech news you missed from the weekend - about 1 year ago Novartis is building a new radioligand plant in China - over 1 year ago Today’s biotech news roundup, in under 800 words - over 1 year ago A new algorithm unveils CRISPR ‘treasure trove’ - over 1 year ago These are the need-to-know biotech stories from this weekend - over 1 year ago XBI biotech index rises, giving investors a shred of hope - over 1 year ago Shrinking Covid vaccine sales has Moderna course-correcting - over 1 year ago Your Monday morning biotech news roundup - over 1 year ago Candor on gene therapy, Abiomed is warned, & BTK success in MS - over 1 year ago Want a biotech buyout? Target cancer - over 1 year ago
2	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	STAT+: Biotech is in a dark place - 19 days ago A biotech’s binary bet ends badly - 9 months ago STAT+: The inside story of Enhertu’s pan-tumor approval - 11 months ago STAT+: Weed for weight loss, and more from Biotech Land - 11 months ago
3	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	STAT+: Is Trump’s new order a reprieve for biotech? - 20 days ago This week in biotech earnings so far - 27 days ago East Asians under-represented in biopharma leadership - about 2 months ago A key decision on compounding is expected this week - 3 months ago Gameto says first baby born using new stem-cell tech - 3 months ago BioMarin’s big day today - 6 months ago STAT+: In light of H5N1 outbreak, U.S. in talks with mRNA vaccine makers on bird flu - 10 months ago
4	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	Beyond GLP-1s? This biotech is exploring longer-term metabolic treatments - 22 days ago Execs from Bayer, Kite and Orca sound off on their launch strategies for cell and gene therapies - 10 months ago 4 offbeat biotechs making a splash in the life sciences - 10 months ago What’s old is new: The revival of a one-time radiotherapy cancer treatment - 11 months ago These biotech hotspots are ripe for IPOs - 12 months ago Black Diamond looks to outwit cancer mutations - about 1 year ago
5	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	4 companies to watch in the accelerating gene editing race - 2 months ago California is a life sciences leader. Joe Panetta has been one of its most vocal advocates. - 5 months ago Who’s winning in biotech’s tight market? - 6 months ago Astellas’ science chief on the leap into new technologies - about 1 year ago PharmaVoice 100s: Entrepreneurs - over 1 year ago Red Jacket: Helen Sabzevari, an immunotherapy pioneer - over 1 year ago
6	Michael Gibney Pharma Voice Teacher of English. Teacher of politics. Santiago, Chile educationpolitics	An RNA biotech draws the blueprint for a late-stage Dravet syndrome trial and beyond - 3 months ago 2024 PharmaVoice 100s: Cell and Gene Therapy Pioneers - 4 months ago 2024 PharmaVoice 100s: Biotech Pathfinders - 4 months ago A biotech’s difficult journey to bring a new kind of Parkinson’s drug to patients - 7 months ago A biotech dousing ‘fires’ in the brain that plagued a bestselling author - 7 months ago A new biotech tackling IBD joins a race against Lilly and Gilead for a promising pill - 8 months ago Protein power: a biotech mining viruses to fight disease - 8 months ago 3 up-and-coming US biotech hotspots - 10 months ago Now a biopharma powerhouse, Vertex’s R&D bedrock could deliver tomorrow’s blockbusters - 10 months ago Biosimilar uptake appears to finally be on the upswing, and Biocon Biologics is betting on the sector’s future - 11 months ago How to make 2024 a banner year for biopharma, despite the headwinds - about 1 year ago One biotech’s 3 gene therapy hurdles: delivery, delivery and delivery - about 1 year ago This biotech aims to expand the CRISPR toolkit for more disease targets in the liver and brain - about 1 year ago How to succeed in biotech: A serial entrepreneur’s tips for surviving tough times - over 1 year ago A biotech tackles drug discovery with transcription factor know-how - over 1 year ago A new delivery method muscling its way into the RNA space - over 1 year ago
7	STAT Staff STAT News Frontiers of health & medicine reporting. healthmedicinejournalism	The biotech updates you need to read this morning - 4 months ago
8	Alex Carchidi Motley Fool Writer, consultant, entrepreneur. Motley Fool. Boston, Massachusetts writingconsultingentrepreneurshipfinance	The Best Biotech Stock to Invest $1,000 in Right Now - 9 months ago
9	Damian Garde STAT News Biotech reporter at STAT. Open to messages. biotechnologyjournalism	Gas prices are hurting biotech - 11 months ago Another step toward new drugs for Parkinson’s - about 1 year ago The clock is ticking, and Cytokinetics is running out of December - about 1 year ago BioMarin appeases an activist - about 1 year ago STAT+: 3 trends to watch in biotech in 2024 - about 1 year ago Is it time to worry about Moderna? - about 1 year ago A plot to solve the ‘whack-a-mole’ of drug discovery - about 1 year ago Tome Biosciences goes public today in another biotech megaround - about 1 year ago Carmot’s chance of beating the odds in the biotech market just ended - about 1 year ago Flagship Pioneering crosses the pond, opens a European front - over 1 year ago Bayer’s new CEO was dealt a duo of ‘clearing events.’ Tough choices lie ahead - over 1 year ago The return of biotech’s “bump factor” amid an economic downturn - over 1 year ago Legend Biotech’s deal with Novartis is a reminder that biotech’s bear market has a few haves, and many have-nots - over 1 year ago BioMarin’s new CEO inherits a profitable company, a pioneering gene therapy, and a brewing activist challenge - over 1 year ago Gene editing has had a big week in the spotlight. Here’s what’s going on - over 1 year ago What if there’s no market for a CRISPR cure? - over 1 year ago Cell and gene therapies could be a safer bet than other drugs - over 1 year ago
10	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	STAT+: How biotech investors spot opportunity when stocks are down — and up - 12 months ago STAT+: Biotech incubator Curie.Bio graduates its first startup - over 1 year ago STAT+: Life science investors close nearly $6 billion in new funds - over 1 year ago

Journalists covering Biotech Spotlight